Showing 6761-6770 of 8179 results for "".
- Roflumilast Foam and Cream Show Promise in Multiple Skin Diseaseshttps://practicaldermatology.com/news/roflumilast-foam-and-cream-show-promise-in-multiple-skin-diseases/2460767/Roflumilast foam significantly improved both scalp and body psoriasis, with improvement as early as two weeks after treatment initiation, data presented at the 2021 AAD VMX show. Additionally, data presented in posters at the AAD VMX show that roflumilast foam is a safe, well-tolerated, and effec
- Promising Phase 3 Data for Oral Deucravacitinib from Bristol Myers Squibb in Psoriasishttps://practicaldermatology.com/news/promising-phase-3-data-for-oral-deucravacitinib-from-bristol-myers-squibb-in-psoriasis/2460765/In two pivotal Phase 3 trials evaluating deucravacitinib 6mg once daily for the treatment of patients with moderate to severe plaque psoriasis, significantly more patients met both co-primary endpoints—Psoriasis Area and Severity Index (PASI) 75 response and a static Physician's Global
- Zoom Dysmorphia Fuels Boost in Cosmetic Consultshttps://practicaldermatology.com/news/zoom-dysmorphia-fuels-boost-in-cosmetic-consults/2460760/During the pandemic, there was a shift to remote work, and demand for video conferencing increased which sired a corresponding rise in the number of patients with negative self-perceptions seeking cosmetic consultations, a new survey shows. In a survey of more than 100 board-certified d
- DermTech Launches DermTech PLAplushttps://practicaldermatology.com/news/dermtech-launches-dermtech-plaplus/2460759/DermTech has launched DermTech PLAplus (TM), its next generation test for the enhanced early detection of melanoma, intended to provide objective and actionable information to guide clinical management decisions for skin lesions suspicious of melanoma.
- Research Reveals How Skin May Repair Itselfhttps://practicaldermatology.com/news/research-reveals-how-skin-may-repair-itself/2460755/Activation of two transcription factors may enhance a natural process of skin cell division, a desirable outcome in regenerative medicine, according to a study in Nucleic Acid Research. In normal conditions, one in every four cells isolated from the inner layer of the skin
- C-Jun Protein May Play Role in Psoriasis Developmenthttps://practicaldermatology.com/news/c-jun-protein-may-play-role-in-psoriasis-development/2460753/The "c-Jun" protein may play a major role in the development of psoriasis, but inhibiting this protein may alleviate symptoms, new research suggests. c-Jun belongs to a larger family of transcription factors, DNA-binding factors, known as Activator Protein-1 (AP-1). Previ
- And The Winners Are...BTL's Emsculpt Classic, Emsculpt NEO, and Emsella.https://practicaldermatology.com/news/and-the-winners-arebtls-emsculpt-classic-emsculpt-neo-and-emsella/2460751/BTL Aesthetics’ took home five awards from several aesthetic publications for Emsculpt Classic, Emsculpt NEO, and Emsella. Emsculpt therapy was named the winner of the 2020 Aestheticians Choice Award for Favorite Body Sculpting Device in Dermascop
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on
- Yale Cancer Center Study Highlights Novel Immunotherapy Approach to Fight Melanomahttps://practicaldermatology.com/news/yale-cancer-center-study-shows-novel-immunotherapy-approach-to-fight-melanoma/2460748/A tumor-targeting and cell-penetrating antibody can stimulate an immune response to help treat melanoma, Yale researchers reported at the American Association of Cancer Research (AACR) virtual annual meeting. “Most approaches rely on direct injection into tumors of ribonucleic aci
- DecisionDx-Melanoma Accurately Predicts Patient Outcomes in Cutaneous Melanomahttps://practicaldermatology.com/news/decisiondx-melanoma-accurately-predicts-patient-outcomes-in-cutaneous-melanoma/2460746/Castle Biosciences, Inc.’s DecisionDx-Melanoma is a significant, independent predictor of patient outcomes in cutaneous melanoma. DecisionDx-Melanoma is Castle’s gene expression profile test that uses an individual patient’s tumor biology to predict risk of cutane